Industry & Business

Diaceutics to Use Artificial Intelligence to Improve Diagnosis and Treatment of Patients

 Breaking News
  • 90 New Jobs at E + I Engineering in Donegal The Taoiseach, Leo Varadkar TD, has announced 90 new jobs at E+I Engineering Ltd in Donegal. E+I Engineering Ltd is a global leader in the critical power distribution sector, manufacturing electrical switchgear, busduct systems and energy management software, for some of the most recognisable brands and technically advanced companies all over the world. Announcing the jobs boost, [...]...
  • €8 Million in Government Funding Awarded by SEAI to Innovative Energy Research Projects The Government has announced €8 million in funding to support 45 innovative energy projects in companies and research institutions across Ireland. The Sustainable Energy Authority of Ireland (SEAI) is responsible for awarding the funding to the 45 projects which aim to develop solutions that will help our homes, businesses and communities deliver a cleaner energy future. [...]...
  • McKeever Hotel Group Renovates Dunadry Hotel in Multi-million Pound Investment McKeever Hotel Group, one of Northern Ireland’s largest family hotel groups, is undertaking a multi-million pound investment designed to revitalise the Dunadry Hotel to a four star, luxury business and leisure venue. The acquisition of the Dunadry Hotel last year was the 5th property to be added to the McKeever Hotel Group portfolio which,  also purchased [...]...
  • Resilient Performance by Breedon Group Breedon Group, a leading construction materials group in the UK and Ireland, has reported revenue of £378.4 million for the six months to 30 June 2018, up from £326.3 million in the corresponding period of 2017. Underlying earnings before interest and tax (EBIT) increased by 17% to £42.0 million. However, excluding acquisitions, both revenue and [...]...
  • 250 New Jobs Announced by Alchemy in Major Investment in Northern Ireland Alchemy Technology Services has announced it is setting up a European Centre of Excellence in Londonderry. It will provide software implementation and technology consultancy to the UK and European insurance sector. The company will provide certified staff to System Integrators, Software Providers and insurance companies for the implementation of digital solutions across the insurance industry. To [...]...

Diaceutics to Use Artificial Intelligence to Improve Diagnosis and Treatment of Patients

Diaceutics to Use Artificial Intelligence to Improve Diagnosis and Treatment of Patients
March 07
09:26 2018

Diaceutics, the Irish company helping patients to receive potentially lifesaving medicine through better diagnostic testing, has announced a collaboration with computer hardware manufacturer Lenovo, and chip manufacturer Intel. The collaboration will enable Diaceutics to leverage their vast proprietary database of patient testing data in a revolutionary way.

Using artificial intelligence (AI) to see whether patients can be grouped according to diagnostic test information, the company is hopeful that this data can help identify ways to improve diagnosis, treatment and outcomes for patients with similar characteristics.

Utilising one of the most powerful workstations on the planet, with the Lenovo ThinkStation P920 powered by Intel Xeon Scalable processors, and a vast amount of complex testing data from hundreds of clinical laboratories, Diaceutics is aiming to get the right medicine to the right individuals at the right time by classifying patient groups and disease patterns.

After a number of biomarkers covering a variety of tumours and cancer types have been inputted, the machine learning system will be able to identify similarities and patterns within the testing data and highlight what is happening among groups of patients. Essentially, the organisation of this information could mean that at-risk patients can be identified, diagnosed and treated much faster.

Considering that an estimated 78,000 cancer patients are not properly tested each year in the United States and therefore are being denied access to potentially lifesaving medication, this collaboration could further transform the area of personalised medicine. Diaceutics has given more than half a million patients the best possible chance of getting to better treatment through better testing.  The findings from the collaboration will be presented at a series of upcoming conferences.

Peter Keeling (pictured), chief executive officer of Diaceutics, said: “Artificial intelligence can make a very strong and positive impact on precision medicine and we are excited to be moving the boundaries with this highly innovative technology. We can now look at data in a novel way. No longer will we only be  making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates.

“This collaboration is a major step in our mission to help patients, by helping them find the right precision medicine at the right time. We are using artificial intelligence to enable the world to unlock the true life changing promise of precision medicine.”

About Author

admin

admin

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4